Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 28, Issue 9, 2010, Pages 1527-1533

  Soria, Jean Charles ^a   Smit, Egbert ^a   Khayat, David ^a   Besse, Benjamin ^a   Yang, Xinqun ^a   Hsu, Cheng Pang ^a   Reese, David ^a   Wiezorek, Jeffrey ^a   Blackhall, Fiona ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DULANERMIN; PACLITAXEL; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FEMALE; FEVER; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; LIVER TOXICITY; LUNG CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RHINITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; LUNG TUMOR; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77951894266     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.4847     Document Type: Article

References (27)

1. Ashkenazi A: Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7:1001-1012, 2008
2. Ashkenazi A: Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19:325-331, 2008
3. Ashkenazi A, Herbst RS: To kill a tumor cell: The potential of proapoptotic receptor agonists. J Clin Invest 118:1979-1990, 2008
4. Ashkenazi A, Holland P, Eckhardt SG: Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26:3621-3630, 2008
5. Rowinsky EK: Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 23:9394-9407, 2005
6. D'Amelio M, Tino E, Cecconi F: The apoptosome: Emerging insights and new potential targets for drug design. Pharm Res 25:740-751, 2008
7. Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162, 1999
8. Lawrence D, Shahrokh Z, Marsters S, et al: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7:383-385, 2001
9. Pollack IF, Erff M, Ashkenazi A: Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 7:1362-1369, 2001 (Pubitemid 32708693)
10. Qin J, Chaturvedi V, Bonish B, et al: Avoiding premature apoptosis of normal epidermal cells. Nat Med 7:385-386, 2001 (Pubitemid 32298515)
11. Gazitt Y: TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13:1817-1824, 1999
12. Mitsiades CS, Treon SP, Mitsiades N, et al: TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications. Blood 98:795-804, 2001
13. Hylander BL, Pitoniak R, Penetrante RB, et al: The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 3:22, 2005
14. Jin H, Yang R, Fong S, et al: Apo2 ligand/ tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 64:4900-4905, 2004 (Pubitemid 38924535)
15. Daniel D, Yang B, Lawrence DA, et al: Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 110:4037-4046, 2007 (Pubitemid 350248460)
16. Naka T, Sugamura K, Hylander BL, et al: Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 62:5800-5806, 2002 (Pubitemid 35204738)
17. Herbst RS, Mendolson DS, Ebbinghaus S, et al: A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J Clin Oncol 24:124s, 2006 (suppl; abstr 3013)
18. Spierings DC, de Vries EG, Timens W, et al: Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 9:3397-3405, 2003 (Pubitemid 37082735)
19. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. Lu JF, Bruno R, Eppler S, et al: Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779-786, 2008
22. Huizing MT, Giaccone G, van Warmerdam LJ, et al: Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer: The European Cancer Centre. J Clin Oncol 15:317-329, 1997 (Pubitemid 27020590)
23. Goffin JR, Anderson IC, Supko JG, et al: Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 11:3417-3424, 2005 (Pubitemid 40627895)
24. Oguri S, Sakakibara T, Mase H, et al: Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 28:208-215, 1988 (Pubitemid 19014767)
25. Nagata S: Apoptosis by death factor. Cell 88:355-365, 1997
26. Taylor K, Micha D, Ranson M, et al: Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain. Expert Opin Investig Drugs 15:669-690, 2006
27. Jo M, Kim TH, Seol DW, et al: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6:564-567, 2000 (Pubitemid 30305907)